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Introduction {#sec1}
============

Immunodeficient animal models play critical roles in biomedical research, such as in the evaluation of stem cell functions *in vivo*. Severe combined immunodeficient (SCID) mice lack an adaptive immune response due to deficiencies in genes such as *Prdkc* ([@bib26]). However, innate immune cells such as natural killer (NK) cells and macrophages can also reject human cells transplanted into mice, and thus significantly reduce the engraftment efficiency of human cells in SCID mice ([@bib27], [@bib28], [@bib31]). These bottlenecks are resolved by the findings that NK cells in mice do not develop after the *Il2rγ* gene is disrupted ([@bib3]). In addition, the inhibitory receptor signal regulatory protein alpha (SIRPα), which is primarily expressed on the surface of monocytes and macrophages, is responsible for the macrophage-mediated rejection of xenografts by sensing through the interaction between SIRPα and CD47 ([@bib13], [@bib20]). Non-obese diabetic (NOD) mice harbor a polymorphism in the *Sirpα* gene that enhances the binding of mouse SIRPα to human CD47, preventing the macrophage-mediated rejection of human cells in NOD mice ([@bib28]). The transgenic expression of human *SIRPα* gene in SCID mice also improves the engraftment of human stem cells ([@bib27], [@bib28], [@bib31]). Therefore, *NODSCIDIl2rγ*^−/−^ (NSG) mice represent an optimized transplantation model for human stem cell research, especially for human hematopoietic stem cells (HSCs). In this context, NSG mice can be efficiently engrafted with human HSCs to reconstitute the human immune system, providing an important *in vivo* model to study human immune responses ([@bib14], [@bib32]). For example, these immune system-humanized mice have been successfully used to study human immune responses to cells derived from human pluripotent stem cells ([@bib9], [@bib24], [@bib33]).

Compared with the mouse, the rat is metabolically and physiologically more similar to humans and is the preferred species for modeling metabolic diseases and carrying out physiological, pharmacological (including pharmacokinetics and pharmacodynamics), and toxicological studies to provide preclinical efficacy and safety data ([@bib6], [@bib7], [@bib16]) ([@bib2], [@bib8]). The rat is also the preferred species to evaluate the behavioral, psychological, and cognitive functions in response to drug treatment and stem cell therapy of neurological diseases ([@bib4], [@bib7], [@bib22]). Because of the enormous difference between the heart rates of mice and humans, the mouse model is inappropriate to evaluate the functions of human stem cell-based therapy of heart diseases. Larger animal models with slower heart rates, such as the rat, are more suitable for this purpose ([@bib29]). In support of this notion, rat models have been extensively used to evaluate the efficacy of human stem cell therapy of heart diseases, such as myocardial infarction and heart failure ([@bib29]). Additionally, compared with mice, the body size of the rat is significantly larger, and thus allows more sophisticated surgical procedures for stem cell transplantation and provides more blood and sample volume to evaluate the efficacy of stem cell-based therapy. Therefore, the NSG rat can serve as a better alternative to the NSG mouse for preclinical evaluation of the efficacy of human stem cell-based therapy.

While the genetic manipulation of the mouse has become routine during the past 40 years, the genetic manipulation of rats has been technically challenging, and NSG rats have not yet been reported. Two recent publications described the generation of *Prkdc*^−/−^ (SCID) and *Il2rγ*^−/−^ rats, which exhibit immunodeficiency similar to that of their mouse counterparts ([@bib19], [@bib18]). However, while the *Prkdc*^−/−^*Il2rγ*^−/−^ (SG) rats lack acquired immunity (B and T cells) and NK cells, they cannot be engrafted with human HSCs due to the macrophage-mediated rejection of human xenografts, as expected from mouse studies ([@bib18]). Therefore, it is necessary to generate NSG rats for human stem cell research.

The breakthrough technology of CRISPR (clustered regularly interspaced short palindromic repeat) and Cas (CRISPR-associated) protein (CRISPR/Cas9 system) has enabled the efficient genetic modification of various animal species, including rats. Taking advantage of the CRISPR/Cas9 technology, we disrupted the *Prkdc* and *Il2rγ* genes in rats. We further established human *SIRPα* (*hSIRPα*) transgenic rats via zygote injection and intercrossed these genetically modified rats to generate *hSIRPα*^+^*Prkdc*^−/−^*Il2rγ*^−/−^ rats, denoted NSG-like (NSGL) rats. Compared with SG rats, NSGL rats can be more efficiently engrafted with human cancer cells and human embryonic stem cells (hESCs), but only NSGL rats can be engrafted with human HSCs. Therefore, the NSGL rats will have broad applications in human stem cell research.

Results {#sec2}
=======

Generation and Characterization of SG and NSGL Rats {#sec2.1}
---------------------------------------------------

To generate *hSIRPα*^+^ transgenic rats, a 200-kb bacterial artificial chromosome (BAC; RP11-993C19) harboring the entire coding region of human *SIRPα* (*hSIRPα*) was linearized and injected into rat zygotes, which were implanted into pseudo-pregnant female rats to generate *hSIRPα*^+^ transgenic rats. Flow cytometric analysis demonstrated the co-expression of rat *Sirpα* (*rSirpα*) and *hSIRPα* on the surface of the leukocytes of the *hSIRPα*^+^ transgenic mice, confirming the successful generation of *hSIRPα*^+^ transgenic mice ([Figure S1](#mmc1){ref-type="supplementary-material"}).

To generate the SCID rats, we employed CRISPR/Cas9 technology to disrupt the rat *Prkdc* gene. Two guide RNAs (gRNAs) were designed to achieve the disruption of the gene ([Figure S2](#mmc1){ref-type="supplementary-material"}A). The sequencing of F1 rats indicated a deletion of 95 bases in the *Prkdc* gene ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Compared with wild-type (WT) rats, the percentage of B and T cells was reduced in the *Prkdc*^+/−^ rats ([Figure S2](#mmc1){ref-type="supplementary-material"}C). The development of B cells was abolished in the *Prkdc*^−/−^ rats, indicating the successful disruption of the *Prkdc* gene ([Figure S2](#mmc1){ref-type="supplementary-material"}C). However, there remained a small fraction of CD4^+^ cells in the *Prkdc*^−/−^ rats, suggesting a leaky mutation that retained a low level of DNA-dependent protein kinase activity similar to that found in SCID mice ([Figures S2](#mmc1){ref-type="supplementary-material"}C). The percentage of NK cells was increased in *Prkdc*^−/−^ rats due to the large reduction of B and T cells ([Figure S2](#mmc1){ref-type="supplementary-material"}C).

We used a similar approach to disrupt the *Il2rγ* gene in the rat, leading to a 662-bp deletion of the *Il2rγ* gene ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). The disruption of the *Il2rγ* gene abolished the development of NK and B cells in rats and significantly reduced the number of T cells in the rats ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Therefore, the *Il2rγ* chain is required for the development of the lymphoid lineages in rats.

To generate rats that are lacking in acquired immunity and NK cells, we intercrossed *Prkdc*^+/−^ *Il2rγ*^+/−^ rats to generate SG rats. While a small fraction of T cells remained in *Prkdc*^−/−^ and *Il2rγ*^−/−^ rats, T cells were abolished in SG rats ([Figures 1](#fig1){ref-type="fig"}A and 1B). We also introduced the *hSIRPα* transgene into the SG background through multiple generations of intercrossing to generate NSGL rats, which express the hSIRPα in leukocytes but do not have B, T, and NK cells ([Figures 1](#fig1){ref-type="fig"}A and 1B).Figure 1Defective Development of B, T, and NK Cells in Various Genetically Mutant Rats(A) NK cells, B cells, and T cells are abolished in SG (*Prdkc*^−/−^*Il2rγ*^−/−^) and NSGL (*hSIRPα*^+^*Prdkc*^−/−^*Il2rγ*^−/−^) rats. In addition, NSGL rats co-expressed human SIRPα and rat SIRPα on the peripheral blood leukocytes. The genotypes are indicated on the top and cell types on the left. The percentage of the gated cells within the CD45^+^ leukocytes is indicated. PBMC, peripheral blood mononuclear cells.(B) Statistical analysis of the percentage of NK cells, B cells, and T cells in the CD45^+^ leukocytes in the peripheral blood of WT (N = 10), SG (N = 14), and NSGL (N = 18) rats. Mean value ± SD are presented. p values are indicated.

NSGL Rats Can Be More Efficiently Engrafted with Human Cancer Cells and hESCs than SG Rats {#sec2.2}
------------------------------------------------------------------------------------------

Based on the roles of SIRPα in the macrophage-mediated rejection of human cells, we predicted that NSGL rats could be more efficiently engrafted with human cells. We first compared the engraftment efficiency of human cancer cells (H460) subcutaneously transplanted in SG and NSGL rats. While the implanted NSGL rats rapidly developed tumors after transplantation, the implanted SG rats developed smaller tumors with slower kinetics ([Figures 2](#fig2){ref-type="fig"}A and 2B). Therefore, NSGL rats can be more efficiently engrafted with human cancer cells than SG rats.Figure 2NSGL Rats Were More Efficiently Engrafted with Human Cancer Cells and hESCs than SG RatsGrowth curve of tumors formed by human lung cancer cells H460 (A) and teratomas formed by H9 hESCs (C) after subcutaneous injection into the SG and NSGL rats. The tumor volume was plotted against the days after transplantation. N = 3. Mean value ± SD are presented. Statistical analysis of the volume and weight of the tumors formed by H460 cells 2 weeks after transplantation (B) or those of the teratomas formed by hESCs at 6 weeks after transplantation (D) in SG and NSGL rats. N = 3. p values are indicated.

hESCs can spontaneously form teratomas after subcutaneous transplantation in NSG mice ([@bib23], [@bib24]). Therefore, we used a teratoma formation assay to compare the engraftment efficiency of hESCs in SG and NSGL rats. After subcutaneous transplantation, all implanted NSGL rats developed teratomas ([Figures 2](#fig2){ref-type="fig"}C and 2D). However, the implanted SG rats either failed to develop teratomas or developed teratomas at a much slower rate ([Figures 2](#fig2){ref-type="fig"}C and 2D). Therefore, NSGL rats can be more efficiently engrafted with hESCs than SG rats.

Engraftment of Human HSCs in SG and NSGL Rats {#sec2.3}
---------------------------------------------

Previous studies have shown that SG mice or rats cannot be engrafted with human HSCs (hHSCs) to reconstitute the human immune system ([@bib18]). Therefore, we tested the possibility of engrafting NSGL rats with hHSCs by transfusing CD34^+^ cells derived from human fetal liver into SG and NSGL rats pre-conditioned with ionizing radiation. Consistent with previous findings ([@bib18]), none of the seven analyzed SG rats transplanted with CD34^+^ hHSCs developed human immune cells up to 10 weeks after implantation ([Figure 3](#fig3){ref-type="fig"}C). In contrast, five of the seven NSGL rats that survived the transfusion developed human CD45^+^ cells in the peripheral blood 5 weeks after transfusion ([Figure 3](#fig3){ref-type="fig"}A). There was an efficient reconstitution of CD19^+^ human B cells in the NSGL rats transfused with human fetal liver CD34^+^ cells ([Figures 3](#fig3){ref-type="fig"}A and 3B). However, there was a lack of human T cells in these rats that was likely due to the absence of human thymus required for efficient human T cell development.Figure 3NSGL Rats Can Be Engrafted with Human Hematopoietic Stem Cells to Develop Multi-lineage hCD45^+^ Human Leukocytes(A and B) Human B cells and macrophages, but not human T cells, were readily detected within the PBMCs (A) and bone marrow (BM) (B) of NSGL rats 5 weeks after being transfused with CD34^+^ human fetal liver cells. The percentage of the hCD45^+^ cells within the leukocyte population is indicated in the top panel. The percentage of human B cells, T cells, and macrophages within the hCD45^+^ human leukocyte population is indicated in the bottom panel. PBMC and BM of the WT rats were used as negative controls for immunostaining.(C) Statistical analysis of the percentage of the hCD45^+^ cells within all leukocytes as well as the percentage of B cells and T cells within the gated hCD45^+^ cell population in SG and NSGL rats transplanted with hHSCs. The engraftment rate (the number of rats with human cell engraftment versus the total rats transplanted) is indicated. Mean values ± SD are presented.

To promote T cell development in NSGL rats engrafted with hHSCs, we transplanted a small piece of autologous human fetal thymus under the renal capsule of pre-conditioned SG and NSGL rats that were simultaneously transfused with hHSCs, as we previously described to establish the mice with a humanized immune system ([@bib9], [@bib24], [@bib33]). While we could not detect any human CD45^+^ cells in six SG rats 5 weeks after being transplanted with CD34^+^ fetal liver cells and fetal thymus, we detected human CD45^+^ cells in six of the seven surviving NSGL rats 5 weeks after transplantation ([Figure 4](#fig4){ref-type="fig"}A). In addition to the reconstitution of human B cells, human T cells were also efficiently reconstituted in the NSGL rats 5 weeks after transplantation ([Figures 4](#fig4){ref-type="fig"}A--4D and [S4](#mmc1){ref-type="supplementary-material"}). Human NK cells and macrophages were easily detectable in the bone marrow of the reconstituted NSGL rats ([Figure 4](#fig4){ref-type="fig"}C). In summary, in contrast to SG rats, NSGL rats can be engrafted with hHSCs to develop a human immune system.Figure 4The reconstitution of Human Immune System in NSGL Rats Engrafted with CD34^+^ Fetal Liver Cells and Autologous Fetal Thymus(A--C) Human B cells, T cells, and NK cells were readily detected in the PBMC (A), spleen (B), and BM (C) of NSGL rats 5 weeks after transplantation. No reconstitution of the immune cells could be detected in SG rats up to 10 weeks after transplantation. The percentage of hCD45^+^ cells within all leukocytes is indicated in the top panels. The percentage of NK cells, macrophages, B cells, and T cells within the gated hCD45^+^ human leukocyte population is indicated in the bottom panels.(D) Statistical analysis of the percentage of the hCD45^+^ cells within all leukocytes as well as the percentage of B cells and T cells within the gated hCD45^+^ cell population in SG and NSGL rats engrafted with CD34^+^ fetal liver cells and autologous fetal thymus. The engraftment rate (the number of rats with human cell engraftment versus the total rats transplanted) is indicated. Mean values ± SD are presented.

Discussion {#sec3}
==========

Immunodeficient animal models have become indispensable transplantation models in stem cell research. Among various experimental animal species, the mouse has become the most extensively used animal species in biomedical research and drug development due to the long-established feasibility of genetically modifying the mouse genome. In this context, mouse ESCs were successfully established more than 40 years ago to allow efficient genetic modification of the mouse genome *in vitro* ([@bib5], [@bib17]), and the development of chimeric mouse technology has enabled the transmission of the genetic mutations of mouse ESCs into the mouse germline ([@bib30]). Various spontaneous and genetically modified immunodeficient mouse models, including nude mice, SCID mice, NSG mice, and *RAG1/2*-deficient mice, have been widely used for biomedical research ([@bib25]). These technical advances have been delayed for other animal species, such as the rat and pig, which are evolutionarily and physiologically closer to humans than the mouse ([@bib1], [@bib7]).

With the accumulating knowledge of the immune responses to human xenografts in mice, it has been well established that both acquired and innate immunity are involved in rejecting human cells transplanted in mice ([@bib27], [@bib28], [@bib31]). Several lines of immunodeficient mice (Nude, SCID or *Prkdc*^−/−^, *RAG1/2* deficient) are defective in acquired immunity ([@bib25]). The innate immunity mediated by NK cells and macrophages is also required for the immune rejection of human cells, especially human stem cells ([@bib10], [@bib11], [@bib12]). These problems are mitigated by the abolishment of NK cells in *Il2Rγ*^−/−^ mice and a mutation in the Sirpα gene of *NOD* mice that prevents macrophage-mediated rejection of human cells by promoting the interaction between mouse SIRPα and human CD47 ([@bib27], [@bib28], [@bib31]). These discoveries led to the generation of NSG mice that are lacking in both innate and acquired immunity. Therefore, NSG mice have become an important transplantation model for human stem cell research ([@bib25]). Considering the significant physiological differences between the mouse and human immune systems, NSG mice reconstituted with a functional human immune system have broad applications in studying human immunity, from infection to cancer and human stem cells ([@bib15], [@bib25]).

Despite the importance of NSG mice in biomedical research, their rat counterparts represent a better xenotransplantation model to evaluate the neural, cardiac, and hepatic functions of stem cell therapy ([@bib1], [@bib21]). Therefore, the establishment of the NSGL rat represents a major advance in preclinical efficacy studies of human stem cell-based therapy. In addition, in contrast to SG rats, only NSGL rats can be engrafted with human HSCs to reconstitute a human immune system. Therefore, once the conditions to reconstitute the human immune system in NSGL rats are optimized, we expect that the NSGL rats and immune system-humanized rats will become important new tools for human stem cell research and therapeutic development.

Experimental Procedures {#sec4}
=======================

Genetic Manipulation of Rats {#sec4.1}
----------------------------

We disrupted the *Prkdc* and *Il2rγ* genes in Sprague-Dawley (SD) rats by injecting a pair of gRNAs and CAS9 mRNA into rat zygotes, which were then implanted into pseudo-pregnant female SD rats. We generated human SIRPα transgenic rats via zygote injection of BAC DNA. The rat genomic DNA used for genotyping was isolated from a small piece of ear. All animal work was approved by the Institutional Animal Care and Use Committee.

Cell Culture {#sec4.2}
------------

The H9 hESCs were cultured on a CF1 mouse embryonic fibroblast feeder layer in DMEM/F12 supplemented with 20% knockout serum replacement, 0.1 mM nonessential amino acids, 2 mM Glutamax, 1% penicillin/streptomycin, 10 ng/mL basic fibroblast growth factor, and 110 μM β-mercaptoethanol. H9 hESCs were dissociated with collagenase type IV (1 mg/mL) and passaged on a feeder layer with a 1:4--1:6 dilution. H460 lung cancer cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, 2 mM Glutamax, 1% penicillin/streptomycin, and 55μM β-mercaptoethanol. All cell culture reagents were purchased from Invitrogen unless indicated otherwise.

Xenotransplantation Studies {#sec4.3}
---------------------------

Five-week-old male rats were subcutaneously injected with human cells. The length (*a*) and width (*b*) of the tumors or teratoma were measured with calipers, using the formula *V* = *ab*^2^/2 to calculate the tumor or teratoma volume (*V*). Female rats 6--10 weeks old were used for the reconstitution of the immune system by transplanting human HSCs and/or fetal thymus cells. After pre-conditioning with sublethal (250 cGy or 200 cGy, 100 cGy/min) total body ionizing irradiation, SG and NSGL rats were intravenously transfused with 1 × 10^6^ human CD34^+^ fetal liver cells with or without implantation of human fetal thymic tissue (1 mm^3^) under the kidney capsule. Human fetal tissues were obtained from Advanced Bioscience Resources (ABR) under informed consent, and their use in this study was approved by ABR as well as University of California, San Diego and Southern Medical University. Human CD34^+^ cells were isolated by a magnetic-activated cell sorter separation system using anti-CD34 microbeads (Miltenyi Biotec) as we previously described ([@bib9], [@bib33]).

Flow Cytometry Analysis {#sec4.4}
-----------------------

The single cell suspension of rat tissues was prepared as previously described ([@bib9]). After the red blood cells were lysed with ammonium-chloride-potassium buffer, the cells were stained with human or rat leukocyte-specific antibodies and analyzed with a BD LSRFortessa cytometer using FlowJo software. The antibodies used were the following: hCD45 (BD Bioscience, 561864), hCD19 (BD Bioscience, 560994), hCD3 (BD Bioscience, 563423), hCD4 (BD Bioscience, 555347), hCD8 (BD Bioscience, 555634), hCD56 (Biolegend, 318332), hCD14 (BD Bioscience, 557831), rCD45 (Biolegend, 202216), rCD45RA (Biolegend, 202318), rCD3 (Biolegend, 201403), rCD4 (Biolegend, 201516), rCD8a (Biolegend, 200610), rCD161a (BD Bioscience, 555009), hSIRPα (Biolegend, 323810), and rSIRPα (Biolegend, 204706).

Statistical Analysis {#sec4.5}
--------------------

All statistical analyses were performed using a two-tailed Student\'s t test with GraphPad Prism 5 software. The mean ± SD and p value are shown. p \< 0.05 indicates statistical significance.
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